Publications

Links below provide research information about Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT).

Highlights From 2016 ASTRO

Acoustic Neuroma/Vestibular Schwannoma

Primary, Metastatic, and Benign Brain Tumors

Pituitary Tumors

Prostate Cancer

Low/Intermediate Risk Prostate Cancer

Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study

Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial

Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer

Hypofractionated Stereotactic Body Radiotherapy in Low-Risk Prostate Adenocarcinoma

Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

Utilizing Time-Driven Activity-Based Costing to Understand the Short- and Long-Term Costs of Treating Localized, Low-Risk Prostate Cancer

SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

Dose-escalated robotic SBRT for stage I–II prostate cancer

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer

Intermediate/High Risk Prostate Cancer

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer/a>

Stereotactic Body Radiotherapy as Boost for Organ-con ned Prostate Cancer/a>

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study/a>

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study/a>

A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer/a>

STEREOTACTIC BODY RADIOTHERAPY AS MONOTHERAPY OR POST–EXTERNAL BEAM RADIOTHERAPY BOOST FOR PROSTATE CANCER: TECHNIQUE, EARLY TOXICITY, AND PSA RESPONSE/a>

SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

Dose-escalated robotic SBRT for stage I–II prostate cancer

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer

Consult with one of our Radiation Oncologists (380) 898-8300